Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (323)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 281 to 290 of 323
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
Technology appraisal guidance
19 March 2025
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
TBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]
Technology appraisal guidance
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259
Technology appraisal guidance
TBC
Previous page
1
…
27
28
Current page
29
30
31
…
33
Page
29
of
33
Next page
Results per page
10
25
50
All
Back to top